| scholarly article | Q13442814 |
| P50 | author | Raphael Schiffmann | Q91521266 |
| P2093 | author name string | Ellen Sidransky | |
| John M Allman | |||
| Ajay Verma | |||
| Glenn D Sandberg | |||
| Alan Morrison | |||
| Alicia Lwin | |||
| Carlos Colegial | |||
| Kondi Wong | |||
| Laura K Wakefield | |||
| Tonghui Mixon | |||
| P2860 | cites work | Sphingolipidoses | Q66707026 |
| Localization of an endoplasmic reticulum calcium ATPase mRNA in rat brain by in situ hybridization | Q67903405 | ||
| Multiple modes of neuronal population activity emerge after modifying specific synapses in a model of the CA3 region of the hippocampus | Q67961120 | ||
| Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain | Q68098239 | ||
| Columnar organization in the subiculum formed by axon branches originating from single CA1 pyramidal neurons in the rat hippocampus | Q69118712 | ||
| Factors affecting the binding of glucosylceramidase to its natural substrate dispersion | Q69393326 | ||
| Gaucher's Disease: Neurologic Disorder in Adult Siblings | Q69541878 | ||
| A quantitative analysis of the dendritic organization of pyramidal cells in the rat hippocampus | Q70938099 | ||
| Determination of Gaucher's disease phenotypes with monoclonal antibody | Q71822780 | ||
| Monoclonal antibodies against human beta-glucocerebrosidase | Q72708933 | ||
| Local synaptic circuits in rat hippocampus: interactions between pyramidal cells | Q72844362 | ||
| alpha-Synuclein membrane interactions and lipid specificity | Q74071513 | ||
| The neuropathology of infantile Gaucher's disease | Q74258136 | ||
| Feedback connections from area MT of the squirrel monkey to areas V1 and V2 | Q74267350 | ||
| Gaucher disease and parkinsonism: a phenotypic and genotypic characterization | Q74386360 | ||
| Gaucher disease associated with parkinsonism: four further case reports | Q78775965 | ||
| Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus | Q28204048 | ||
| Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes | Q29617606 | ||
| Neurological involvement in type 1 (adult) Gaucher's disease | Q33620764 | ||
| Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease | Q34082413 | ||
| Management of neuronopathic Gaucher disease: a European consensus. | Q34326941 | ||
| Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease | Q36312252 | ||
| Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein | Q36677512 | ||
| Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils | Q39632694 | ||
| The synaptic nature of the paroxysmal depolarizing shift in hippocampal neurons | Q40079359 | ||
| Calcium pools mobilized by calcium or inositol 1,4,5-trisphosphate are differentially localized in rat heart and brain | Q40241162 | ||
| Rat brain endoplasmic reticulum calcium pools are anatomically and functionally segregated | Q40641865 | ||
| Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status | Q40868687 | ||
| Activity of the phosphatidylcholine biosynthetic pathway modulates the distribution of fatty acids into glycerolipids in proliferating cells. | Q40901145 | ||
| Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation | Q40964871 | ||
| Occurrence of Parkinson's syndrome in type I Gaucher disease | Q41211077 | ||
| Topographically organized reciprocal connections between areas 17 and MT (visual area of superior temporal sulcus) in the marmoset Callithrix jacchus | Q41249040 | ||
| Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses | Q41382443 | ||
| Familial Psychosis and Diverse Neurologic Abnormalities in Adult-Onset Gaucher's Disease | Q41438249 | ||
| Giant synaptic potential hypothesis for epileptiform activity | Q41648071 | ||
| alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease | Q41676981 | ||
| Excitatory synaptic interactions between CA3 neurones in the guinea-pig hippocampus | Q41904635 | ||
| Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease | Q42213816 | ||
| Type 2 and type 3 Gaucher disease: a morphological and biochemical study | Q42221976 | ||
| Specificity of human glucosylceramide beta-glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system | Q42222879 | ||
| Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies | Q42251245 | ||
| Central nervous system involvement in adult-onset Gaucher's disease | Q42271503 | ||
| Organization of CA1 projections to the subiculum: A PHA-L analysis in the rat | Q42467841 | ||
| The hippocampal CA3 network: an in vivo intracellular labeling study | Q42504912 | ||
| Intrinsic connections of macaque striate cortex: afferent and efferent connections of lamina 4C. | Q44063118 | ||
| Solubilization of glucocerebrosidase from human placenta and demonstration of a phospholipid requirement for its catalytic activity | Q44113753 | ||
| Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide | Q44132494 | ||
| Aggresome-related biogenesis of Lewy bodies | Q44242992 | ||
| Cytotoxicity of ventricular cerebrospinal fluid from Parkinson patients: correlation with clinical profiles and neurochemistry. | Q44300712 | ||
| Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms | Q44412880 | ||
| Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? | Q44479792 | ||
| Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons | Q48153561 | ||
| Parkinson's syndrome preceding clinical manifestation of Gaucher's disease | Q48168785 | ||
| Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. | Q48384247 | ||
| Selective neurofibrillary degeneration of the hippocampal CA2 sector is associated with four-repeat tauopathies | Q48425178 | ||
| Laminar organization of geniculocortical projections in Galago senegalensis and Aotus trivirgatus | Q48426246 | ||
| Thalamic and other subcortical projections to area MT (visual area of superior temporal sulcus) in the marmoset Callithrix jacchus | Q48429413 | ||
| Hippocampal lesions in the neuronal ceroid lipofuscinoses | Q48763209 | ||
| Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings | Q48820932 | ||
| Inositol trisphosphate and thapsigargin discriminate endoplasmic reticulum stores of calcium in rat brain | Q48875724 | ||
| Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease | Q49037384 | ||
| Acute infantile Gaucher's disease in identical twins. An account of clinical and neuropathologic observations | Q49063038 | ||
| Areal and laminar distribution of neurons interconnecting the central visual cortical areas 17, 18, 19, and MT in squirrel monkey (Saimiri) | Q49158667 | ||
| Coactivation of Local Circuit NMDA Receptor Mediated epsps Induces Lasting Enhancement of Minimal Schaffer Collateral epsps in Slices of Rat Hippocampus | Q51710723 | ||
| Membrane binding and self-association of alpha-synucleins | Q52543652 | ||
| Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p | Q57982330 | ||
| Selective hippocampal neuron loss in dementia with Lewy bodies | Q59544658 | ||
| P433 | issue | 3 | |
| P921 | main subject | Gaucher's disease | Q861645 |
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 192-207 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Molecular Genetics and Metabolism | Q6895949 |
| P1476 | title | Neuropathology provides clues to the pathophysiology of Gaucher disease | |
| P478 | volume | 82 |
| Q38110488 | "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide |
| Q37135478 | 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. |
| Q47389795 | A Focus on the Beneficial Effects of Alpha Synuclein and a Re-appraisal of Synucleinopathies |
| Q41436833 | A Lysosomal Lair for a Pathogenic Protein Pair |
| Q37346468 | A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies |
| Q33727058 | Aberrant Ca2+ handling in lysosomal storage disorders |
| Q41871999 | Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models |
| Q35960402 | Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations |
| Q47289706 | Altered Differentiation Potential of Gaucher's Disease iPSC Neuronal Progenitors due to Wnt/β-Catenin Downregulation |
| Q57295636 | Altered brain functional network in children with type 1 Gaucher disease: a longitudinal graph theory-based study |
| Q42617617 | Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress |
| Q48314813 | Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease |
| Q35231770 | Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies |
| Q36639634 | Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. |
| Q37939781 | Animal models for Gaucher disease research |
| Q48522524 | Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III. |
| Q36332588 | Astrocytes and lysosomal storage diseases |
| Q34555995 | Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation |
| Q36653957 | Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies |
| Q37528927 | Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease |
| Q26771552 | Autophagy, lipophagy and lysosomal lipid storage disorders |
| Q83404983 | Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging |
| Q35094391 | Bridging molecular genetics and biomarkers in lewy body and related disorders |
| Q35122963 | CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy |
| Q41952618 | CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings |
| Q48824358 | Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease |
| Q92590277 | Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease |
| Q53325232 | Clinical characteristics of the neurological forms of Gaucher's disease |
| Q30409165 | Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease |
| Q45267679 | Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction |
| Q48526137 | Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease |
| Q58599923 | Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum |
| Q39730152 | Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. |
| Q36961324 | Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels |
| Q34238616 | Development of targeted therapies for Parkinson's disease and related synucleinopathies |
| Q33634529 | Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease |
| Q39366291 | Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. |
| Q47321665 | Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. |
| Q52689754 | Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease |
| Q34185956 | Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease |
| Q37785328 | Emerging parkinsonian phenotypes |
| Q39667264 | Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease |
| Q35955350 | Exploring the link between glucocerebrosidase mutations and parkinsonism |
| Q89521816 | Fabry Disease With Concomitant Lewy Body Disease |
| Q36777244 | GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A. |
| Q30527838 | GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology |
| Q64226316 | Gaucher Disease: New Expanded Classification Emphasizing Neurological Features |
| Q36076437 | Gaucher disease and parkinsonism |
| Q34348780 | Gaucher disease and parkinsonism, a molecular link theory |
| Q34795306 | Gaucher disease and the synucleinopathies |
| Q34037141 | Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization |
| Q24307627 | Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies |
| Q47232538 | Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition. |
| Q38533848 | Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry |
| Q104802177 | Gaucher disease: Basic and translational science needs for more complete therapy and management |
| Q39028972 | Gaucher disease: Progress and ongoing challenges |
| Q35908938 | Gaucher disease: complexity in a "simple" disorder |
| Q34556549 | Gaucher disease: pathological mechanisms and modern management |
| Q28534109 | Gaucher disease: transcriptome analyses using microarray or mRNA sequencing in a Gba1 mutant mouse model treated with velaglucerase alfa or imiglucerase |
| Q35851610 | Gaucher-Associated Parkinsonism |
| Q38237560 | Genetic convergence of Parkinson's disease and lysosomal storage disorders |
| Q64073224 | Glial phagocytic clearance in Parkinson's disease |
| Q27005669 | Glucocerebrosidase and Parkinson disease: Recent advances |
| Q87497276 | Glucocerebrosidase and parkinsonism: lessons to learn |
| Q40196691 | Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. |
| Q36801004 | Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains |
| Q42513965 | Glucocerebrosidase expression patterns in the non-human primate brain. |
| Q38811401 | Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment |
| Q39253252 | Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage |
| Q38007465 | Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. |
| Q35960413 | Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders |
| Q36389683 | Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease |
| Q38161987 | Glucocerebrosidase mutations and the pathogenesis of Parkinson disease |
| Q84214782 | Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease |
| Q30483458 | Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease |
| Q24656668 | Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease |
| Q36487922 | Glucocerebrosidase mutations in diffuse Lewy body disease |
| Q48161565 | Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. |
| Q38084062 | Glucocerebrosidase, a new player changing the old rules in Lewy body diseases |
| Q31072456 | Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data |
| Q38605208 | Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson's disease. |
| Q38168763 | Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development |
| Q64865269 | Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease |
| Q36481546 | Inborn errors of metabolism: the flux from Mendelian to complex diseases. |
| Q39254537 | Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned? |
| Q36898538 | Induction of the type I interferon response in neurological forms of Gaucher disease |
| Q28588670 | LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance |
| Q34478663 | Lewy bodies |
| Q36794105 | Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt |
| Q28118642 | Loss of β-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells |
| Q89879079 | Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease |
| Q39914071 | Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity |
| Q33843073 | Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease |
| Q37461364 | Lysosomal impairment in Parkinson's disease |
| Q57060151 | Lysosomal storage diseases |
| Q37880734 | Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond |
| Q48795615 | Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease |
| Q38038561 | Lysosome-dependent pathways as a unifying theme in Parkinson's disease. |
| Q93129259 | Measuring disease activity and patient experience remotely using wearable technology and a mobile phone app: outcomes from a pilot study in Gaucher disease |
| Q38648684 | Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids |
| Q33918923 | Mesenchymal stem cells as cellular vectors for pediatric neurological disorders |
| Q37882589 | Milestones in PD genetics |
| Q47147993 | Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson's Disease |
| Q28115678 | Mitochondrial dysfunction associated with glucocerebrosidase deficiency |
| Q51767278 | Modeling Parkinson's Disease in C. elegans |
| Q39364713 | Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice |
| Q37350413 | Molecular and cellular biology of synucleins |
| Q47611385 | Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease |
| Q37231887 | More than hypomyelination in Pol-III disorder |
| Q31159730 | Movement disorders and inborn errors of metabolism in adults: a diagnostic approach |
| Q33902037 | Multi-system disorders of glycosphingolipid and ganglioside metabolism |
| Q33847578 | Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice |
| Q30480646 | Murine models of acute neuronopathic Gaucher disease |
| Q37983366 | Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. |
| Q90717467 | Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy |
| Q28512774 | Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction |
| Q48140722 | Neurological and brain MRS findings in patients with Gaucher disease type 1. |
| Q57468485 | Neurological effects of GBA mutations |
| Q33373178 | Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed? |
| Q31137458 | Neurological presentations of lysosomal diseases in adult patients |
| Q41887691 | Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration |
| Q39357071 | Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits |
| Q36302109 | Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model |
| Q34464236 | Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds |
| Q38116812 | Neuronopathic lysosomal storage diseases: clinical and pathologic findings. |
| Q37827417 | Neuropathic Gaucher disease |
| Q34256752 | Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB |
| Q47619453 | Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature |
| Q38164875 | Niemann-Pick's and Gaucher's diseases |
| Q42439041 | Niemann‐Pick disease type C1 predominantly involving the frontotemporal region, with cortical and brainstem Lewy bodies: An autopsy case |
| Q43792274 | Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease |
| Q30248574 | Parkinson Disease and Dementia |
| Q30852543 | Parkinson disease in Gaucher disease. |
| Q29616302 | Parkinson's disease |
| Q38647777 | Parkinson's disease pathogenesis from the viewpoint of small fish models |
| Q38727638 | Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance |
| Q22242870 | Parkinson's disease: from monogenic forms to genetic susceptibility factors |
| Q44299994 | Parkinson’s disease in patients and obligate carriers of Gaucher disease |
| Q36362062 | Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuum |
| Q34907714 | Phenotype, diagnosis, and treatment of Gaucher's disease |
| Q36123828 | Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease |
| Q50239146 | Progressive myoclonic epilepsy and horizontal gaze palsy: a rare aetiology |
| Q35589803 | Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology |
| Q86977777 | Proton MR Spectroscopy of the brain in children with neuronopathic Gaucher’s disease |
| Q37686264 | Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration |
| Q54383542 | RIPK3 as a potential therapeutic target for Gaucher's disease |
| Q48032967 | Reduced cerebral vascularization in experimental neuronopathic Gaucher disease. |
| Q47241738 | Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. |
| Q58856637 | Scientific correspondence |
| Q27643401 | Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease |
| Q39386374 | Survival and dementia in GBA-associated Parkinson's disease: The mutation matters |
| Q35982198 | Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice |
| Q28482370 | Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease |
| Q38118169 | The Association Between ß-Glucocerebrosidase Mutations and Parkinsonism |
| Q26744716 | The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease |
| Q38012653 | The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders |
| Q42136746 | The Spectrum of Neurological Manifestations Associated with Gaucher Disease |
| Q33780681 | The Video Head Impulse Test |
| Q37329304 | The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism |
| Q36315252 | The cognitive profile of type 1 Gaucher disease patients |
| Q34604083 | The genetics of Parkinson disease |
| Q64861724 | The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress |
| Q92713972 | The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease |
| Q34077492 | The link between the GBA gene and parkinsonism |
| Q36124421 | The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow |
| Q57613018 | The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG) |
| Q37997386 | The neuropathology of genetic Parkinson's disease |
| Q34336776 | The pallidopyramidal syndromes: nosology, aetiology and pathogenesis |
| Q36486264 | The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders |
| Q26862604 | The role of saposin C in Gaucher disease |
| Q31027711 | The saccadic and neurological deficits in type 3 Gaucher disease |
| Q38217376 | The significance of GBA for Parkinson's disease |
| Q53143606 | Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. |
| Q27311396 | Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein |
| Q33937498 | Visual short-term memory deficits associated with GBA mutation and Parkinson's disease |
| Q28548589 | Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes |
| Q83374306 | [Central nervous system involvement in Gaucher disease] |
| Q90099972 | mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells |
| Q38039369 | α-Synuclein and Neuronal Cell Death |
| Q36718306 | α-Synuclein oligomers and clinical implications for Parkinson disease |
| Q36607556 | α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models |
| Q84539110 | β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease |
Search more.